Company / Interest Expense
Cardiff Oncology, Inc. Interest Expense History
FY2016-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$2.0K
FY2021
5-year range
$2.0K / $2.0K
FY2017-FY2021
Trend
+0.0%
vs FY2020
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Increased from $0 to $2,000 over the past 2 years.
Based on SEC 10-K filings.
$2,000 in FY2021 with a 3-year CAGR of -87.5%.
Increased from $0 to $2,000 over the past 2 years.
Interest Expense over time
Growth rates
- 3-Year CAGR
- -87.5%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -87.5%, indicating a declining trend.
- In FY2021, interest expense increased 0.0% year-over-year.
- Peak interest expense was recorded in FY2017.
- Lowest interest expense in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -6.67 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | $2.0K | +0.0% |
| FY2020 | $2.0K | - |
| FY2019 | $0 | -100.0% |
| FY2018 | $1.0M | -38.2% |
| FY2017 | $1.7M | +301.5% |
| FY2016 | -$831.0K | -154.5% |
As of FY2021 · SEC 10-K · Updated Jun 24, 2026